Angiotensin-converting enzyme inhibition changes the metabolic response to neuroglucopenic stress

• Published in: Journal of the renin-angiotensin-aldosterone system Vol. 12; no. 3; pp. 153 - 160
• Main Authors: Carvalho Miranda, Paulo Augusto, Simões e Silva, Ana Cristina, de Oliveira Longo, Junia Ribeiro, Magalhães Madureira, Marcos, Bastos Fóscolo, Rodrigo, Campos Machado, Lucas José, Vilas Boas, Walkíria Wingester, dos Santos, Robson Augusto, Celso Coimbra, Candido, Ribeiro-Oliveira, Antônio
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.09.2011
• Subjects: Angiotensin-Converting Enzyme Inhibitors - pharmacology; Animals; Blood Glucose - drug effects; Body Weight - drug effects; Cholesterol - blood; Deoxyglucose - administration & dosage; Deoxyglucose - pharmacology; Drinking Behavior - drug effects; Enalapril - administration & dosage; Enalapril - pharmacology; Glucose - metabolism; Insulin - blood; Male; Neurons - drug effects; Neurons - metabolism; Neurons - pathology; Peptidyl-Dipeptidase A - metabolism; Rats; Stress, Physiological - drug effects; Time Factors; Triglycerides - blood; Weight Gain - drug effects; neuroglucopenia; angiotensin; stress; insulin; ACE inhibitors; enalapril
• ISSN: 1470-3203; 1752-8976
• DOI: 10.1177/1470320310390726

Neuroglucopenia induced by 2-deoxy-D-glucose (2DG) activates hypothalamic glucoreceptors leading to increased hepatic glucose production and insulin inhibition. This response is similar to what is observed with intravenous injection of angiotensin II (Ang II). However, the involvement of an angiotensin-converting enzyme inhibitor on neuroglucopenia has not been investigated. The aim of this study was to determine the effects of chronic enalapril treatment on plasma glucose, insulin and lipid levels in response to neuroglucopenia. Male Holtzman rats (120—170 g) were chronically treated with enalapril (10 mg/kg per day) in the drinking water for two weeks. On the day of experiment the animals received an i.v. enalapril final dose one hour before the neuroglucopenic stress by 2DG infusion (500 mg/kg), and blood samples were drawn before and 5, 10, 20, 30 and 60 minutes following infusion. The hyperglycaemic response to 2DG was not significantly changed by enalapril treatment. The enalapril-treated group exhibited a peak of plasma insulin higher than controls. Plasma triglyceride showed a significant increase only in the enalapril group after neuroglucopenic stress (p < 0.05).These data show that chronic enalapril treatment changes insulin and triglyceride responses to neuroglucopenia, suggesting an effect on glucose-induced insulin secretion and the storage of triglycerides.